ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

Thyroid-Stimulating Hormone and Prolactin Levels in a Population-based Sample of Women Aged 25 to 45

DOI:10.31550/1727-2378-2019-165-10-46-51
Bibliography link: Rymar O.D., Voevoda S.M., Denisova D.V., Shakhtshneider E.V., Stakhnyova E.M., Shcherbakova L.V. Thyroid-Stimulating Hormone and Prolactin Levels in a Population-based Sample of Women Aged 25 to 45. Doctor.Ru. 2019; 10(165): 46–51. (in Russian) DOI: 10.31550/1727-2378-2019-165-10-46-51
Thyroid-Stimulating Hormone and Prolactin Levels in a Population-based Sample of Women Aged 25 to 45
11 September 07:44

Objective of the Study: To evaluate thyroid-stimulating hormone (TSH) and prolactin (PRL) levels and their interrelationships in a population-based sample of women aged 25 to 45.

Study Design: This was a cross-sectional study.

Materials and Methods: A representative sample of women aged 25 to 45 was examined. The mean subject age was 36.0 ± 6.2 years. PRL and TSH levels were measured by ELISA in 416 women.

Study Results: The median TSH level in the study participants was 1.48 [0.98; 2.19] IU/ml, and the median level of PRL was 12.13 [6.75; 18.85] ng/ml. There was no significant difference in the median TSH and PRL levels in four subgroups (25–29, 30–34, 35–39, and 40–45 years of age) did not show any significant differences (р = 0.559 and р = 0.197, using the Kruskal-Wallis H test). In women without menstrual or thyroid disorders, the median TSH level was 1.49 [1.02; 2.06] IU/ml and PRL was 10.79 [5.92; 17.12] ng/ml, while in those with menstrual and/or thyroid disorders, these levels were 1.43 [0.86; 2.63] IU/ml and 14.34 [8.54; 21.35] ng/ml, respectively, with the difference in PRL levels being statistically significant (p = 0.001). There was a tendency toward an increase in TSH (within the normal range) in women stratified into quartiles by PRL, despite a significant increase in the median PRL level in the fourth quartile compared with the first (4.51 [3.56; 5.48] – 24.38 [21.33; 30.45]; р = 0.078). There was a significant difference in the TSH levels in women stratified into quartiles by PRL, using the Kruskal-Wallis H test (р = 0.044). In the study sample as a whole, there was a weak correlation between TSH and PRL levels; the Spearman's rank correlation coefficient (Rs) was 0.09 (р = 0.067). The study revealed a higher proportion of women with elevated TSH and PRL levels among the participants who had reported menstrual disorders than among those without such problems, although the difference was not statistically significant.

Conclusion: Among females with or without menstrual disorders, the proportion of women who have elevated PRL levels is higher than that of women with elevated TSH levels. Thus, hyperprolactinemia is a common condition in young women with menstrual disorders. Based on these screening data, we plan to perform further examinations of these women to determine the causes of hyperprolactinemia and provide necessary treatment.

Financing: This study was carried out within the framework a budget-funded project, which was part of government-mandated program No. 0324-2018-0001 (No. АААА-А17-117112850280-2), entitled “Epidemiological monitoring of public health and evaluation of molecular genetic and molecular biology mechanisms of common medical conditions in people living in Siberia: improving approaches to diagnosis, prevention, and treatment”.

Contribution: Rymar, O.D. — study design, thematic publications reviewing, review of critically important material, participation in preparation of all sections and conclusion, approval of the manuscript for publication; Voevoda, S.M. — subjects selection, sampling, thematic publications reviewing, data analysis and interpretation, manuscript preparation; Denisova, D.V. — organised for screening of men and women aged 25–44 in Novosibirsk, article reviewing; Shakhtshneider, E.V. — participation in preparation of “Material and Methods” section, Stakhneva, E.M. — participation in preparation of “Material and Methods” section, data interpretation; Scherbakova, L.V. — database compilation, data analysis and interpretation, participation in manuscript preparation.

 

 

Conflict of interes: The authors declare that they do not have any conflict of interests.


O.D. Rymar — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 8345-9365. E-mail: Orymar23@gmail.com

S.M. Voevoda — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 4403-6722. E-mail: sm.voevoda@mail.ru

D.V. Denisova — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 9829-7692. E-mail: denisovadiana@gmail.com

E.V. Shakhtshneider — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 9453-9067. E-mail: 2117409@mail.ru

E.M. Stakhnyova — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 7154-5094. E-mail: Stahneva@yandex.ru

L.V. Shcherbakova — Research Institute for Therapeutic and Preventive Medicine, a branch of the Federal Research Center — Institute of Cytology and Genetics (a Federal Government-funded Scientific Institution), Siberian Branch of the Russian Academy of Sciences; 175/1 Boris Bogatkov St., Novosibirsk, Russian Federation 630089. eLIBRARY.RU SPIN: 5849-7040. E-mail: 9584792@mail.ru


Thyroid-Stimulating Hormone and Prolactin Levels in a Population-based Sample of Women Aged 25 to 45
11 September 07:44
LITERATURE
  1. Sirohi T., Singh H. Estimation of serum prolactin levels and determination of prevalence of hyperprolactinemia in newly diagnosed cases of subclinical hypothyroidism. J. Family Med. Prim. Care. 2018; 7(6): 1279–82. DOI: 10.4103/jfmpc.jfmpc_155_18
  2. Chen A.X., Burt M.G. Hyperprolactinaemia. Aust. Prescr. 2017; 40(6): 220–4. DOI: 10.18773/austprescr.2017.060
  3. Poppe K., Velkeniers B., Glinoer D. Thyroid disorders in infertile women. Clin. Endocrinol. (Oxf). 2007; 66(3): 309–21. DOI:10.1111/j.1365-2265.2007.02752.x
  4. Vilar L., Fleseri M., Bronstein M.D. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq. Bras. Endocrinol. Metab. 2014; 58(1) 9–22. DOI: 10.1590/0004-2730000003002
  5. Morreale de Escobar G., Obregon M.J., Escobar del Rey F. Role of thyroid hormone during early brain development. Eur. J. Endocrinol. 2004; 151(suppl.3): U25–37.
  6. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2011; 96(2): 273–88. DOI: 10.1210/jc.2010-1692
  7. Halperin Rabinovich I., Gómez R.C., García Mouriz M., Ollero García-Agulló D. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinol. Nutr. 2013; 60(6): 308–19. DOI: 10.1016/j.endonu.2012.11.005
  8. Anciferov M.B., Sviridenko N.Yu. Sindrom gipotireoza: diagnostika i lechenie. Metodicheskie rekomendacii. M.: NPC EHMP; 2005. 26 s. (in Russian)
  9. Mel'nichenko G.A., Rozhinskaya L.Ya., Dzeranova L.K., Pigarova E.A., Romantsova T.I., Grineva E.N. i dr. Federal'nye klinicheskie rekomendacii po giperprolaktinemii: klinika, diagnostika, differencial'naya diagnostika i metody lecheniya. M.; 2015. 19 s. (in Russian)
  10. Dedov I.I., Mel'nichenko G.A. Endokrinologiya: nacional'noe rukovodstvo. M.: GEHOTAR-Media; 2013. 1072 s. (in Russian)
  11. Shrestha S., Neupane S., Gautam N., Dubey R.K., Jha A.Ch., Doshi N.R. et al. Association of thyroid profile and prolactin level in patient with secondary amenorrhea. Malays J. Med. Sci. 2016; 23(5): 51–6. DOI: 10.21315/mjms2016.23.5.7
  12. Bassey I.E., Udoh A.E., Essien O.E., Isong I.K., Gali R.M., Archibong E.E. Thyroid hormones and prolactin levels in infertile women in Southern Nigeria. J. Clin. Diagnostic Res. 2015; 9(3): OC13–15. DOI: 10.7860/JCDR/2015/11505.5659
  13. Bheem P., Dinesh P., Sharma N.C. A study on serum FSH, LH and prolactin levels among infertile women. Int. J. Med. Res. Health Sci. 2015; 4(4): 876–8. DOI: 10.5958/2319-5886.2015.00175.7
  14. Noor ul Ain, Rehman H.A., Abdullah F.E. Correlation of prolactin and thyroid hormone levels in infertile women: a cross- sectional study in Pakistan. J. Clin. Exp. Pathol. 2017; 7(1): 304. DOI: 10.4172/2161-0681.1000304
  15. Binita G., Suprava P., Mainak C., Koner B.C., Alpana S. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J. Reprod. Infertil. 2009; 10(3): 207–12.
  16. Nad' Yu.G. Sochetanie giperprolaktinemii i subklinicheskogo gipotireoza. Med. sovet. 2009; 2: 42–4. (in Russian)
  17. Sharma L.K., Sharma N., Gadpayle A.K., Dutta D. Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. Eur. J. Intern. Med. 2016; 35: 106–10. DOI: 10.1016/j.ejim.2016.07.012
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners